苏格兰质量绩效指标项目提升非肌层浸润性膀胱癌经尿道膀胱肿瘤电切术的质量与效果
苏格兰于2014年4月在全国实施12项强制性循证质量绩效指标(QPI),其中4项与经尿道膀胱肿瘤电切术(TURBT)相关。该研究前瞻性纳入2014年4月至2017年3月所有新发膀胱癌患者,随访2689例,评估TURBT相关质量指标依从性及非肌层浸润性膀胱癌(NMIBC)的临床结局。结果显示,QPI项目实施与低早期复发/残留癌及准确病理分期相关。
要点
- TURBT后单次即刻灌注丝裂霉素C(SPI-MMC)使用率为67%(2029/3023)。
- 首次随访膀胱镜检查复发率(RRFFC)为13%(116/888),二次TURBT残留癌率为33%(212/653),pT2率为2.9%(19/653)。
- 标本存在逼尿肌可将pT1癌残留病变可能性减半。
核心结论
- 苏格兰QPI项目实施似有助于高质量TURBT,真实世界中与低早期复发/残留癌及准确病理分期相关。
研究设计与样本
- 前瞻性收集2014年4月至2017年3月所有新发膀胱癌患者数据,纳入2689例随访数据。
- 在稳健治理框架下,12项强制性循证QPI于2014年4月在全国实施。
主要发现
- 在4246例新发膀胱癌患者中,NMIBC患者SPI-MMC使用率为67%(2029/3023)。
- 在1860例接受TURBT的NMIBC患者中,RRFFC为13%(116/888),二次TURBT残留癌率为33%(212/653),pT2率为2.9%(19/653)。
- SPI-MMC与较低RRFFC相关,独立于包括医院容量和外科医生在内的所有变量。
- 标本存在逼尿肌可将pT1癌残留病变可能性减半。
关键数值与推荐
- TURBT相关QPI包括:使用膀胱示意图、TURBT后单次即刻灌注丝裂霉素C(SPI-MMC)、标本含逼尿肌、高危NMIBC早期二次TURBT。
临床怎么用
- 实施QPI项目可能促进高质量TURBT,真实世界中与低早期复发/残留癌及准确病理分期相关。
局限性
- 主要局限性是缺乏QPI实施前的对照队列用于比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical outcomes from non-muscle-invasive bladder cancer (NMIBC) are partly determined by the quality of initial interventions. To improve and standardise treatment for cancer, Scotland implemented a national Quality Performance Indicator (QPI) programme for bladder cancer (BC). OBJECTIVE: To evaluate compliance with specific quality indicators (QIs) related to transurethral resection of bladder tumour (TURBT) and to understand clinical outcomes from NMIBC following the introduction of the QPI programme. DESIGN, SETTING, AND PARTICIPANTS: Within a robust governance framework, 12 mandatory evidence-based QPIs were implemented nationally in April 2014. We report prospectively collected data for all new BC patients (between April 2014 and March 2017). We include follow-up data for 2689 patients. INTERVENTION: The TURBT-related QPIs were (1) using a bladder diagram, (2) single post-TURBT instillation of mitomycin C (SPI-MMC), (3) detrusor muscle (DM) in the specimen, and (4) early re-TURBT in high-risk NMIBC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We measured compliance with these QPIs and (1) recurrence rate at first follow-up cystoscopy (RRFFC), (2) rates of residual cancer, and (3) pT2 cancer at re-TURBT. Associations between QPI compliance, tumour features, and outcomes were assessed with multivariable logistic regression models. RESULTS AND LIMITATIONS: Among 4246 new BC patients, SPI-MMC was used in 67% (2029/3023) NMIBC patients. In 1860 NMIBC patients undergoing TURBT, RRFFC, rate of residual cancer, and rate of pT2 at re-TURBT were 13% (116/888), 33% (212/653), and 2.9% (19/653), respectively. SPI-MMC was associated with lower RRFFC, independent of all variables including hospital volume and surgeon. Presence of DM in the specimen halved the likelihood of residual disease in pT1 cancers. The main limitation is the lack of a pre-QPI introduction cohort for comparison. CONCLUSIONS: The implementation of a QI programme in Scotland appears to facilitate high-quality TURBT, which in a real-world setting is associated with low early recurrence/residual cancer and accurate pathological staging. PATIENT SUMMARY: Following the first 3 yr of implementing a novel Quality Performance Indicator (QPI) programme in Scotland, we assessed compliance and outcomes in non-muscle-invasive bladder cancer. Evaluating over 4000 new bladder cancer patients, we found that the QPI programme was associated with low recurrence and accurate staging following the initial transurethral resection of bladder tumour.
引用
- Mariappan P, Johnston A, Padovani L, et al. Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme. Eur Urol. 2020. PMID: 32690321. doi:10.1016/j.eururo.2020.06.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。